The discovery and development of romidepsin for the treatment of T-cell lymphoma.

about

Chromobacterium spp. mediate their anti-Plasmodium activity through secretion of the histone deacetylase inhibitor romidepsin.Chromatin remodeling controls Kaposi's sarcoma-associated herpesvirus reactivation from latency

P2860

Q53693963-119FD4FC-E431-4121-940A-420204328B17 Q58744047-31BD98B1-EC1E-4D92-B6AE-758FE1093CF4

P2860

The discovery and development of romidepsin for the treatment of T-cell lymphoma.

Item

http://www.wikidata.org/entity/Q38713744

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

The discovery and development of romidepsin for the treatment of T-cell lymphoma.

@en

type

Item

label

The discovery and development of romidepsin for the treatment of T-cell lymphoma.

@en

prefLabel

The discovery and development of romidepsin for the treatment of T-cell lymphoma.

@en

P1476

The discovery and development of romidepsin for the treatment of T-cell lymphoma.

@en

P2093

Piotr Smolewski

http://www.w3.org/2001/XMLSchema#string

Tadeusz Robak

http://www.w3.org/2001/XMLSchema#string

P2860

Translating the Histone Code

Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas

Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain

Romidepsin for the treatment of relapsed/refractory cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome): Use in a community setting

Competitive recruitment of CBP and Rb-HDAC regulates UBF acetylation and ribosomal transcription

Roles of histone acetyltransferases and deacetylases in gene regulation

Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing.

Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry.

Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data

A phase I trial of depsipeptide (FR901228) in patients with advanced cancer.

P304

859-873

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/17460441.2017.1341487

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28641053

http://www.w3.org/2001/XMLSchema#string

The discovery and development of romidepsin for the treatment of T-cell lymphoma.

about

P2860

P2860

The discovery and development of romidepsin for the treatment of T-cell lymphoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698